Considerable efforts have been made since the 1950s to better understand the cellular and
molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now …

Incretin‐based therapies, such as the injectable glucagon‐like peptide‐1 (GLP‐1) receptor
agonists and orally administered dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have recently …

Background Diabetes treatments are needed that are convenient, provide effective
glycaemic control, and do not cause weight gain. We aimed to test the hypothesis that …

ETC-1002 (8-hydroxy-2, 2, 14, 14-tetramethylpentadecanedioic acid) is a novel
investigational drug being developed for the treatment of dyslipidemia and other cardio …

The prevalence of diabetes is rising all over the world due to population growth, aging,
urbanisation and an increase of obesity and physical inactivity. Unlike in the West, where …

Hematologic malignancies (HMs) mainly include acute and chronic leukemia, lymphoma,
myeloma and other heterogeneous tumors that seriously threaten human life and health …

Background The current strategies for prevention and treatment of insulin resistance and
type 2 diabetes are not fully effective and frequently accompanied by many negative effects …

Context: Despite the availability of efficacious anti-diabetic drugs, which act by different
mechanisms to reduce the blood-glucose, the majority of people with diabetes on anti …

Metformin has been widely used as a first-line anti-diabetic medicine for the treatment of
type 2 diabetes (T2D). As a drug that primarily targets the liver, metformin suppresses …

Diabetics have higher morbidity and mortality in cardiovascular disease (CVD). A variety of
antidiabetic agents are available for clinical choice. Cardiovascular (CV) safety assessment …